Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCAGN01949 + Immune Therapies in Advanced Malignancies
NCT03241173Phase 2Completed
- Sponsor
- Incyte
- Start
- Oct 2017
- Primary completion
- Sep 2019
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of INCAGN01949 in solid tumor (advanced stage), gastric cancer (GC), squamous cell carcinoma of the head and neck (HNSCC) and 2 more (7 arms), sponsored by Incyte. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events up to 17.4 months, Number of Participants With a Grade 3 or Higher TEAE up to 17.4 months and 1 more. Started Oct 2017; status: completed.
02
Drugs
INCAGN01949
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)squamous cell carcinoma of the head and neck (HNSCC)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03241173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241173.